Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)

22 January 2025

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 9, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Yellox, bromfenac, Date of authorisation: 18/05/2011, Revision: 12, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Sunosi, solriamfetol, Date of authorisation: 16/01/2020, Revision: 9, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 42, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): M-M-RVaxPro, measles, mumps and rubella vaccine (live), Date of authorisation: 05/05/2006, Revision: 34, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma), dabigatran etexilate, Date of authorisation: 19/02/2024, Revision: 4, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Date of authorisation: 22/07/2016, Revision: 13, Status: Authorised

21 January 2025

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 10, Status: Authorised

21 January 2025

PSUSA/00000026/202405

21 January 2025